Targeted Therapy Shows Promise Against Aggressive Meningiomas, Alliance Trial Finds
A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that abemaciclib, an oral cancer drug, may slow tumor growth in patients with aggressive meningiomas that have specific genetic mutations. This primary analysis of Alliance A071401 is published in Nature Medicine. Meningiomas, tumors that grow in the membranes that surround…